Anthera Pharmaceuticals Inc Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014	FY2013 12 months to Dec 31, 2013
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Realized loss on short-term investments
Stock-based compensation expense
Change in fair value of warrant liability
Common stock issued to settle a license fee obligation
Amortization of discount and deferred interest on notes payable
Amortization of debt issuance cost
Fair value of warrant liability in excess of proceeds from financing

Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses and other current assets
Accounts payable
Accrued clinical expenses
Accrued payroll
Other accrued liabilities
Deferred revenue
Net cash used in operating activities
Cash flows from investing activities:
Property and equipment purchases
Proceeds from maturities of short-term investments
Decrease in restricted cash
Net cash provided by (used in) investing activities

Net cash used in investing activities
Cash flows from financing activities:
Proceeds from issuance of notes payable, net of issuance costs
Net proceeds from issuance of preferred stock, warrants and options
Principal payment against note payable
Proceeds from issuance of common stock, net of offering costs
Net proceeds from issuance of common stock pursuant to an equity purchase agreement
Net proceeds from issuance of common stock pursuant to an at-market issuance sales agreement
Net proceeds from issuance of common stock and warrants pursuant to equity offerings
Net proceeds from issuance of common stock pursuant to equity offerings
Net proceeds from issuance of common stock to collaborative partner
Net proceeds from issuance of common stock pursuant to exercise of warrants
Net proceeds from issuance of common stock pursuant to exercise of stock options and employee stock purchase plan
Withholding taxes paid on vested restricted stock units
Net cash provided by (used in) financing activities

Effect of exchange rate changes on cash
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid for interest
Issuance of common stock as a commitment fee pursuant to an equity purchase agreement
Issuance of common stock to settle a license fee obligation
Fair value of warrants issued in connection with registered direct offering

Comments